<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36642173</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-0691</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</Title><ISOAbbreviation>Clin Microbiol Infect</ISOAbbreviation></Journal><ArticleTitle>A systematic review of trials currently investigating therapeutic modalities for post-acute COVID-19 syndrome and registered on WHO International Clinical Trials Platform.</ArticleTitle><Pagination><StartPage>570</StartPage><EndPage>577</EndPage><MedlinePgn>570-577</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmi.2023.01.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1198-743X(23)00009-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Post-acute COVID-19 syndrome (PACS) is a well-recognized, complex, systemic disease which is associated with substantial morbidity. There is a paucity of established interventions for the treatment of patients with this syndrome.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To systematically review registered trials currently investigating therapeutic modalities for PACS.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">A search was conducted up to the 16 September, 2022, using the COVID-19 section of the WHO Internal Clinical Trials Registry Platform.</AbstractText><AbstractText Label="STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS" NlmCategory="METHODS">Interventional clinical trials of any sample size examining any therapeutic modality targeting persistent symptoms among individuals after diagnosis with COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data on trial characteristics and intervention characteristics were collected and summarized.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After screening 17&#xa0;125 trials, 388 trials, from 42 countries, were eligible. In total, we had 406 interventions, of which 368 were mono-therapeutic strategies, whereas 38 were intervention combinations. Among 824 primary outcomes identified, there were &gt;300 different outcomes. Rehabilitation was the most employed class of intervention in 169 trials. We encountered 76 trials examining the pharmacological agents of various classes, with the most common agent being colchicine. Complementary and alternative medicine encompassed 64 trials exploring traditional Chinese medicine, Ayurveda, homeopathic medications, naturopathic medications, vitamins, dietary supplements, and botanicals. Psychotherapeutic and educational interventions were also employed in 12 and 4 trials, respectively. Other interventions, including transcranial direct current stimulation, transcutaneous auricular vagus nerve stimulation, general electrical stimulation, cranial electrotherapy stimulation, various stem cell interventions, and oxygen therapy interventions, were also employed.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We identified 388 registered trials, with a high degree of heterogeneity, exploring 144 unique mono-therapeutic interventions for PACS. Most studies target general alleviation of symptoms. There is a need for further high-quality and methodologically robust PACS treatment trials to be conducted with standardization of outcomes while following WHO's recommendation for uniform evaluation and treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fawzy</LastName><ForeName>Nader A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abou Shaar</LastName><ForeName>Bader</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taha</LastName><ForeName>Rand M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arabi</LastName><ForeName>Tarek Z</ForeName><Initials>TZ</Initials><AffiliationInfo><Affiliation>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabbah</LastName><ForeName>Belal N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alkodaymi</LastName><ForeName>Mohamad S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Family and Community Medicine, Alfaisal University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omrani</LastName><ForeName>Osama A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>University College Hospital, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makhzoum</LastName><ForeName>Tariq</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almahfoudh</LastName><ForeName>Najwa E</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Hammad</LastName><ForeName>Qasem A</ForeName><Initials>QA</Initials><AffiliationInfo><Affiliation>College of Medicine, King Faisal University, Al Ahsa, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hejazi</LastName><ForeName>Wed</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obeidat</LastName><ForeName>Yasin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>UMass Chan Medical School, Baystate, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osman</LastName><ForeName>Naden</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Kattan</LastName><ForeName>Khaled M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berbari</LastName><ForeName>Elie F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tleyjeh</LastName><ForeName>Imad M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, United States; Infectious Diseases Section, Department of Medical Specialties, King Fahad Medical City, Riyadh, Saudi Arabia; Division of Epidemiology, Mayo Clinic College of Medicine and Science, Rochester, MN, United States. Electronic address: Tleyjeh.Imad@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Microbiol Infect</MedlineTA><NlmUniqueID>9516420</NlmUniqueID><ISSNLinking>1198-743X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065908" MajorTopicYN="Y">Transcranial Direct Current Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>15</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36642173</ArticleId><ArticleId IdType="pmc">PMC9837206</ArticleId><ArticleId IdType="doi">10.1016/j.cmi.2023.01.007</ArticleId><ArticleId IdType="pii">S1198-743X(23)00009-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Choutka J., Jansari V., Hornig M., Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28:911&#x2013;923. doi: 10.1038/s41591-022-01810-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>SeyedAlinaghi S.A., Afsahi A.M., MohsseniPour M., Behnezhad F., Salehi M.A., Barzegary A., et al. Archives of Academic Emergency Medicine. Shaheed Beheshti University of Medical Sciences and Health Services; 2020. Late complications of COVID-19; a systematic review of current evidence: Vol. 9; p. e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7927752</ArticleId><ArticleId IdType="pubmed">33681819</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira Almeida K., Nogueira Alves I.G., de Queiroz R.S., de Castro M.R., Gomes V.A., Santos Fontoura F.C., et al. A systematic review on physical function, activities of daily living and health-related quality of life in COVID-19 survivors. Chronic Illn. 2022 doi: 10.1177/17423953221089309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17423953221089309</ArticleId><ArticleId IdType="pmc">PMC9006095</ArticleId><ArticleId IdType="pubmed">35404175</ArticleId></ArticleIdList></Reference><Reference><Citation>Almas T., Malik J., Alsubai A.K., Zaidi S.M., Iqbal R., Khan K., et al. Post-acute COVID-19 syndrome and its prolonged effects: an updated systematic review. Ann Med Surg. 2022;80 doi: 10.1016/j.amsu.2022.103995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2022.103995</ArticleId><ArticleId IdType="pmc">PMC9197790</ArticleId><ArticleId IdType="pubmed">35721785</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q., Li J., Hu X., Bai Y., Zheng Y., Gao Z. Follow-ups on persistent symptoms and pulmonary function among post-acute COVID-19 patients: a systematic review and meta-analysis. Front Med. 2021;8 doi: 10.3389/fmed.2021.702635.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.702635</ArticleId><ArticleId IdType="pmc">PMC8448290</ArticleId><ArticleId IdType="pubmed">34540862</ArticleId></ArticleIdList></Reference><Reference><Citation>Fugazzaro S., Contri A., Esseroukh O., Kaleci S., Croci S., Massari M., et al. Rehabilitation interventions for post-acute COVID-19 syndrome: a systematic review. Int J Environ Res Public Health. 2022;19:5185. doi: 10.3390/ijerph19095185.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19095185</ArticleId><ArticleId IdType="pmc">PMC9104923</ArticleId><ArticleId IdType="pubmed">35564579</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera Martimbianco A.L., Pacheco R.L., Bagattini &#xc2;.M., Riera R. Frequency, signs and symptoms, and criteria adopted for long COVID-19: a systematic review. Int J Clin Pract. 2021;75 doi: 10.1111/ijcp.14357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14357</ArticleId><ArticleId IdType="pmc">PMC8236920</ArticleId><ArticleId IdType="pubmed">33977626</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P., Patel K., Pinto C., Jaiswal R., Tirupathi R., Pillai S., et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)&#x2014;a systematic review and meta-analysis. J&#xa0;Med Virol. 2022;94:253&#x2013;262. doi: 10.1002/jmv.27309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27309</ArticleId><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkodaymi M.S., Omrani O.A., Fawzy N.A., Shaar B.A., Almamlouk R., Riaz M., et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28:657&#x2013;666. doi: 10.1016/j.cmi.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8812092</ArticleId><ArticleId IdType="pubmed">35124265</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (UK)   2020. COVID-19 rapid guideline: managing the long-term effects of COVID-19.https://www.nice.org.uk/guidance/ng188</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  . 2021. A&#xa0;clinical case definition of post COVID-19 condition by a Delphi consensus.https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes L.D., Ingram J., Sculthorpe N.F. More than 100 persistent symptoms of SARS-CoV-2 (long COVID): a scoping review. Front Med. 2021;8 doi: 10.3389/fmed.2021.750378.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.750378</ArticleId><ArticleId IdType="pmc">PMC8591053</ArticleId><ArticleId IdType="pubmed">34790680</ArticleId></ArticleIdList></Reference><Reference><Citation>Joli J., Buck P., Zipfel S., Stengel A. Post-COVID-19 fatigue: a systematic review. Front Psychiatry. 2022;13 doi: 10.3389/fpsyt.2022.947973.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2022.947973</ArticleId><ArticleId IdType="pmc">PMC9403611</ArticleId><ArticleId IdType="pubmed">36032234</ArticleId></ArticleIdList></Reference><Reference><Citation>International Clinical Trials Registry Platform  . 2022. Important information related to the COVID-19 outbreak.https://www.who.int/clinical-trials-registry-platform</Citation></Reference><Reference><Citation>International Clinical Trials Registry Platform  . 2009. WHO registry criteria.https://www.who.int/clinical-trials-registry-platform/network/registry-criteria</Citation></Reference><Reference><Citation>Schardt C., Adams M.B., Owens T., Keitz S., Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7:1&#x2013;6. doi: 10.1186/1472-6947-7-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6947-7-16</ArticleId><ArticleId IdType="pmc">PMC1904193</ArticleId><ArticleId IdType="pubmed">17573961</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1186/s13643-021-01626-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-021-01626-4</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodd S., Clarke M., Becker L., Mavergames C., Fish R., Williamson P.R. A&#xa0;taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. J&#xa0;Clin Epidemiol. 2018;96:84&#x2013;92. doi: 10.1016/j.jclinepi.2017.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2017.12.020</ArticleId><ArticleId IdType="pmc">PMC5854263</ArticleId><ArticleId IdType="pubmed">29288712</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  . 2021. Rehabilitation.https://www.who.int/news-room/fact-sheets/detail/rehabilitation</Citation></Reference><Reference><Citation>WHO Collaborating Centre for Drug Statistics Methodology  . 2022. ATC/DDD index.https://www.whocc.no/atc_ddd_index/</Citation></Reference><Reference><Citation>European Medicines Agency  . 2022. Medicines.https://www.ema.europa.eu/en/medicines</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration  . 2022. Information by drug class.https://www.fda.gov/drugs/drug-safety-and-availability/information-drug-class</Citation></Reference><Reference><Citation>Royal Pharmaceutical Society of Great Britain  . 2022. The traditional herbal medicine registration scheme.https://www.rpharms.com/resources/quick-reference-guides/herbal-medicine-registration-scheme#moreinfo</Citation></Reference><Reference><Citation>Gov.uk  . 2022. Herbal medicines granted a traditional herbal registration.https://www.gov.uk/government/publications/herbal-medicines-granted-a-traditional-herbal-registration-thr/herbal-medicines-granted-a-traditional-herbal-registration</Citation></Reference><Reference><Citation>National Institute of Health (NIH) NC for C. IH (NCCIH)   2022. Herbs at a glance.https://www.nccih.nih.gov/health/herbsataglance</Citation></Reference><Reference><Citation>National Cancer Institute  . 2021. Complementary and alternative medicine.https://www.cancer.gov/about-cancer/treatment/cam</Citation></Reference><Reference><Citation>World Health Organization  . 2022. WHO coronavirus (COVID-19) dashboard.https://covid19.who.int/</Citation></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615. doi: 10.5281/zenodo.4669937.</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.4669937</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Salholz-Hillel M., Grabitz P., Pugh-Jones M., Strech D., DeVito N.J. Results availability and timeliness of registered COVID-19 clinical trials: interim cross-sectional results from the DIRECCT study. BMJ Open. 2021;11 doi: 10.5281/zenodo.4669937.</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.4669937</ArticleId><ArticleId IdType="pmc">PMC8609493</ArticleId><ArticleId IdType="pubmed">34810189</ArticleId></ArticleIdList></Reference><Reference><Citation>Speich B., Gloy V.L., Klatte K., Gryaznov D., Heravi A.T., Ghosh N., et al. Reliability of trial information across registries for trials with multiple registrations. JAMA Netw Open. 2021;4 doi: 10.1001/jamanetworkopen.2021.28898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28898</ArticleId><ArticleId IdType="pmc">PMC8561329</ArticleId><ArticleId IdType="pubmed">34724557</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse T., Fain K.M., Zarin D.A. How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider. BMJ. 2018;361:k1452. doi: 10.1136/bmj.k1452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k1452</ArticleId><ArticleId IdType="pmc">PMC5968400</ArticleId><ArticleId IdType="pubmed">29802130</ArticleId></ArticleIdList></Reference><Reference><Citation>Hr&#xf3;bjartsson A., Emanuelsson F., Skou Thomsen A.S., Hilden J., Brorson S. Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. Int J Epidemiol. 2014;43:1272&#x2013;1283. doi: 10.1093/ije/dyu115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyu115</ArticleId><ArticleId IdType="pmc">PMC4258786</ArticleId><ArticleId IdType="pubmed">24881045</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannister B.A. Post-infectious disease syndrome. Postgrad Med J. 1988;64:559&#x2013;567. doi: 10.1136/pgmj.64.753.559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/pgmj.64.753.559</ArticleId><ArticleId IdType="pmc">PMC2428896</ArticleId><ArticleId IdType="pubmed">3074289</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie I., Davenport T., Wakefield D., Vollmer-Conna U., Cameron B., Vernon S.D., et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333:575. doi: 10.1136/bmj.38933.585764.AE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.38933.585764.AE</ArticleId><ArticleId IdType="pmc">PMC1569956</ArticleId><ArticleId IdType="pubmed">16950834</ArticleId></ArticleIdList></Reference><Reference><Citation>BioWorld  . 2022. EU boosts funding for COVID-19 epidemic, encourages clinical trial cooperation.https://www.bioworld.com/articles/433824-eu-boosts-funding-for-covid-19-epidemic-encourages-clinical-trial-cooperation?v=preview</Citation></Reference><Reference><Citation>WHO  . 2022. COVID-19 solidarity therapeutics trial.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments</Citation></Reference><Reference><Citation>National Institutes of Health  . 2022. RECOVER: researching COVID to enhance recovery.https://recovercovid.org/</Citation></Reference><Reference><Citation>WHO. Cochrane  . 2022. The COVID-NMA initiative: a living mapping and living systematic review of Covid-19 trials.https://covid-nma.com/</Citation></Reference><Reference><Citation>Infectious Diseases Data Observatory  . 2022. A&#xa0;living systematic review of registered COVID-19 trials.https://www.iddo.org/covid-19/live-systematic-review-trials</Citation></Reference><Reference><Citation>Kuang Z., Li X., Cai J., Chen Y., Qiu X., Ni X. Calling for improved quality in the registration of traditional Chinese medicine during the public health emergency: a survey of trial registries for COVID-19, H1N1, and SARS. Trials. 2021;22:188. doi: 10.1186/s13063-021-05182-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-021-05182-z</ArticleId><ArticleId IdType="pmc">PMC7934977</ArticleId><ArticleId IdType="pubmed">33673845</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A.W., Tetzlaff J.M., Gotzsche P.C., Altman D.G., Mann H., Berlin J.A., et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346 doi: 10.1136/bmj.e7586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e7586</ArticleId><ArticleId IdType="pmc">PMC3541470</ArticleId><ArticleId IdType="pubmed">23303884</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz K.F., Altman D.G., Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. doi: 10.4103/0976-500X.72352.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0976-500X.72352</ArticleId><ArticleId IdType="pmc">PMC2844940</ArticleId><ArticleId IdType="pubmed">20332509</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A.W., Hr&#xf3;bjartsson A. Promoting public access to clinical trial protocols: challenges and recommendations. Trials. 2018;19:116. doi: 10.1186/s13063-018-2510-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-018-2510-1</ArticleId><ArticleId IdType="pmc">PMC5816550</ArticleId><ArticleId IdType="pubmed">29454390</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T., Hittle M., Goodman S.N. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19. JAMA Netw Open. 2021;4 doi: 10.1001/jamanetworkopen.2021.11417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Pletcher M.J., Pignone M. Evaluating the clinical utility of a biomarker. Circulation. 2011;123:1116&#x2013;1124. doi: 10.1161/CIRCULATIONAHA.110.943860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.943860</ArticleId><ArticleId IdType="pmc">PMC3138723</ArticleId><ArticleId IdType="pubmed">21403122</ArticleId></ArticleIdList></Reference><Reference><Citation>Selleck M.J., Senthil M., Wall N.R. Making meaningful clinical use of biomarkers. Biomark Insights. 2017;12 doi: 10.1177/1177271917715236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1177271917715236</ArticleId><ArticleId IdType="pmc">PMC5479428</ArticleId><ArticleId IdType="pubmed">28659713</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D., Nicholson T., Akrami A., Apfelbacher C., Chen J., de Groote W., et al. A&#xa0;core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir Med. 2022;10:715&#x2013;724. doi: 10.1016/S2213-2600(22)00169-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00169-2</ArticleId><ArticleId IdType="pmc">PMC9197249</ArticleId><ArticleId IdType="pubmed">35714658</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>